Adults (typically ≥18 years old) with known or suspected Coronary Artery Disease.

Able to undergo coronary CT angiography (CCTA).

May include those with risk factors such as hypertension, high cholesterol, diabetes, or family history of heart disease.

Willing and able to provide informed consent.

Contraindications to contrast-enhanced CT imaging, such as iodine allergy or impaired kidney function.

History of coronary interventions (e.g., stents or bypass surgery) that may interfere with imaging results.

Significant cardiac arrhythmias that could affect image quality.

Pregnancy or women who are breastfeeding.

Any condition that may limit the participant’s ability to comply with study procedures.

Access to advanced cardiovascular imaging and analysis at no cost.

Detailed insights into personal heart health and CAD risk profile.

Study-related care from experienced physicians and clinical staff.

May receive compensation for time and travel.

No requirement for personal health insurance.

Adults ≥18 years old with a clinical diagnosis of ESKD.

On maintenance hemodialysis or peritoneal dialysis.

Documented history of ASCVD (e.g., prior myocardial infarction, coronary revascularization)
– or –
Diagnosis of Type 1 or Type 2 Diabetes Mellitus.

Clinically stable for dialysis treatment.

History of recent major cardiovascular events (e.g., MI or stroke within 3 months).

Active infections, liver disease, or uncontrolled hypertension.

Known hypersensitivity to CSL112, blood-derived products, or excipients.

Pregnant or breastfeeding women.

Participation in another investigational study within 30 days prior to screening.

Free access to investigational medication (CSL112) and all study-related procedures.

Close medical monitoring by board-certified physicians and trained research staff.

Possible reduction in cardiovascular event risk for patients with ESKD and ASCVD or diabetes.

Compensation may be provided for time and travel.

No personal insurance required to participate.

Adults aged 18–85 years.

Diagnosed with gout.

At least 2 gout flares in the past 12 months.

Body weight ≥ 50 kg.

sUA ≥ 7 mg/dL if not on urate-lowering therapy (ULT); sUA > 6 mg/dL if on ULT.

Kidney function: serum creatinine < 3.0 mg/dL, CLcr ≥ 30 mL/min.

History of cancer (except for non-invasive skin cancers) in the last 5 years.

Pregnant or breastfeeding women.

Kidney stones within the past 6 months.

Participants may receive study-related care from experienced physicians and clinical staff at no cost.

Study medication (AR882 or placebo) will be provided free of charge throughout the trial.

Regular health evaluations including lab tests, physical exams, and monitoring of gout-related symptoms.

Potential reduction in serum uric acid levels and gout flare frequency, depending on individual response.

Participants may be compensated for time and travel related to study visits.

No health insurance is required to participate in the study.

Adults ≥18 years of age

Presence of a chronic venous leg ulcer (typically ≥4 weeks in duration)

Ulcer size and location within protocol-defined limits

Adequate arterial blood flow to the affected limb

Willing and able to comply with the study protocol and visits

Informed consent obtained

Presence of active infection or osteomyelitis at the ulcer site

Non-venous etiology for the ulcer (e.g., arterial, diabetic, or pressure ulcers)

Use of investigational wound therapy within 30 days prior to screening

Significant comorbid conditions that could interfere with healing or assessment

Pregnancy or breastfeeding

Current or planned participation in another clinical study that may interfere with outcomes

Access to investigational therapy at no cost

Regular evaluations and advanced wound care

Supervision by an experienced multidisciplinary wound care team

Potential for improved healing outcomes compared to standard of care

Travel compensation may be offered

D4325C00010

Currently receiving or planning to start dialysis within 3 months

Renal transplant recipients

Type 1 diabetes mellitus

Severe hepatic disease

Active malignancy (with few exceptions)

Pregnancy or breastfeeding

Any condition that may, in the opinion of the investigator, affect safety or study compliance

Access to an investigational medication designed to slow kidney damage progression

Regular health monitoring and laboratory testing at no cost

Support by a qualified nephrology research team

Travel compensation may be available

Contributing to the advancement of kidney disease treatments that may benefit millions

Access to an investigational therapy that may offer renal protective benefits

No-cost study medication, laboratory testing, and medical exams

Ongoing monitoring by experienced clinical research professionals

Potential early detection and management of worsening kidney function

Travel support and participant compensation (site dependent)

STABLECAMP

Adults ≥18 years of age

Presence of a chronic DFU or VLU that has not healed with standard care for at least 4 weeks

Adequate circulation to the affected limb, confirmed by vascular assessment

Willingness to comply with study visits and protocol

Written informed consent provided

Infected wounds or presence of osteomyelitis at the ulcer site

Wounds with exposed bone, tendon, or joint capsule

Use of investigational wound care therapies within the past 30 days

Significant uncontrolled comorbidities, including active malignancy or severe peripheral arterial disease

Pregnant or breastfeeding women

Any condition that, in the opinion of the investigator, may interfere with the study outcomes or participant safety

Access to advanced investigational therapy for chronic wound healing at no cost

Comprehensive wound care assessments by a specialized team

Monitoring by experienced clinicians throughout the trial

Potential for improved healing outcomes

Compensation for time and travel may be offered